Related Experiment Video

Updated: Aug 14, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K

Hemodynamic Changes after Continuing or Omitting Regular Angiotensin Converting Enzyme Inhibitors before Cataract

Saeed Khademi1, Reza Jouybar1, Sedigheh Ahmadi1

  • 1Department of Anesthesiology, Shiraz University of Medical Sciences, Shiraz, Iran.

Current Hypertension Reviews
|January 13, 2023
PubMed

Insights

Discontinuing or continuing Angiotensin Receptor Blockers (ARBs) and Angiotensin-Converting Enzyme Inhibitors (ACEIs) did not significantly impact hemodynamic changes in patients undergoing cataract surgery. This suggests current medication management may be safe for this patient group during minor procedures.

Area of Science:

  • Anesthesiology
  • Cardiology
  • Pharmacology

Background:

  • Angiotensin Receptor Blockers (ARBs) and Angiotensin-Converting Enzyme Inhibitors (ACEIs) are commonly prescribed for cardiovascular conditions.
  • Management of these medications around elective surgeries, particularly minor procedures like cataract surgery, requires careful consideration due to potential hemodynamic effects.

Purpose of the Study:

  • To evaluate the impact of continuing versus discontinuing ARBs and ACEIs on hemodynamic parameters during and after cataract surgery.
  • To determine if medication management strategies influence patient safety and outcomes in this surgical context.

Main Methods:

  • A randomized study involving patients aged 40-70 (ASA class II) on ACEI/ARB therapy undergoing cataract surgery.
  • Patients were divided into two groups: one continuing ACEI/ARB use and the other discontinuing it prior to surgery.
  • Hemodynamic data (heart rate, systolic and diastolic blood pressure) were collected before, during, and after anesthesia induction.

Main Results:

  • No significant differences were observed in demographic variables between the groups.
  • While time significantly affected blood pressure and heart rate (p<0.001), there was no significant interaction between time and treatment group.
  • Group effects on systolic blood pressure, diastolic blood pressure, and heart rate were not statistically significant (p > 0.05).

Conclusions:

  • Continuing or discontinuing ACEIs/ARBs does not appear to significantly affect hemodynamic stability (hypotension, heart rate) in patients undergoing minor procedures like cataract surgery.
  • These findings suggest that current practices for managing ACEI/ARB therapy around cataract surgery may be safe.
  • Further research could explore other surgical types or patient populations.
Abstract

Keywords:
Cataractangiotensin receptor blockersangiotensin-converting enzyme inhibitorsblood pressurecardiovascular diseaseheart rate

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.9K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

238

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
745
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
731
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
518
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
806
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
608